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The human IL-6 promoter contains multiple regulatory elements such as those binding transcription factors belonging to the NF-nB
( 75/ 63), C/EBP ( 158/ 145 and  87/ 76) and AP-1 ( 283/ 277) families. Herein, we report that ectopic expression of c-Jun,
C/EBPy, and the p65 subunit of NF-nB synergistically activates an IL-6 promoter construct containing only a TATA box and a nB binding
site. These results suggest that interactions among NF-nB, C/EBP, and AP-1, which are all activated by the most powerful physiological
inducers of the IL-6 gene, namely TNF-a and IL-1, may be crucial for maximal activation of the IL-6 promoter in response to the two
cytokines. Furthermore, we show that a mutated form of c-Jun lacking the transactivation domain (TAM-67) was a much stronger activator of
the IL-6 promoter than c-Jun. In combination with p65 and/or C/EBPy, TAM-67 also synergistically activated the IL-6 promoter, while it
inhibited TNF-a induced AP-1 activity directing an AP-1-responsive reporter plasmid. Lastly, electrophoretic mobility shift assay (EMSA)
results strongly suggest the formation of complexes between p65, C/EBPy, and/or c-Jun or TAM-67 on the nB site, supporting the idea that
the functional synergism is determined by a physical interaction. These data provide new insight into the molecular mechanisms regulating
the formation of the transcription complex responsible for IL-6 promoter activation.
D 2004 Elsevier B.V. All rights reserved.Keywords: Interleukin-6; Transcription; Transfection; NF-nB; C/EBP; AP-1
1. Introduction cytoplasm bound to a member of the InB family of in-Interleukin-6 (IL-6) is a pleiotropic cytokine that plays a
major role in immunological responses, inflammation, bone
metabolism, neoplasia, and aging [1–3]. A number of tran-
scription factors contribute to the complex regulation of the
IL-6 gene and their interactions may vary depending on the
cell type as well as the extracellular stimuli. Functional cis-
regulatory elements described to date in the human IL-6
promoter include IRF-1 ( 267 to  254) [4], AP-1 ( 283
to  277) [5], C/EBP ( 158 to  145 and  87 to  76)
[6,7], Sp1 ( 123 to  119 and  108 to  104) [8,9] and
NF-nB ( 75 to  63) [10] binding sites.
NF-nB belongs to the Rel family of transcription factors
that form homo- or heterodimers through the Rel homology
domain [7,11]. In most cells, NF-nB is present in the0167-4889/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
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1 These authors contributed equally to this work.hibitors [12,13]. Upon activation of the cells by cytokines,
such as TNF-a and IL-1, viruses, bacteria, or mitogens, InB
is phosphorylated and then rapidly degraded allowing the
translocation of NF-nB to the nucleus where it binds to
specific DNA binding sites.
The C/EBP family of transcription factors belongs to a
class of DNA binding proteins called bZIP proteins, which
are characterized by a basic leucine-zipper structure that is
responsible for their homo- and hetero-dimerization [7].
Two members of the family, C/EBPh and C/EBPy, have
been shown to play a role in the induction of the IL-6 gene
[14,15]. C/EBPh is expressed at low levels and is strongly
induced by TNF-a, IL-1, LPS or IL-6 in normal tissues,
whereas it is expressed constitutively in many cell lines
[14]. C/EBPy, which is a stronger transactivator than C/
EBPh of the IL-6 gene transcription, is normally expressed
at low levels and is markedly induced by TNF-a, IL-1,
LPS, or IL-6 in normal tissues and cell lines [15]. Both C/
EBPh [7] and C/EBPy [16] have been shown to increase
their transcriptional potential following phosphorylation.
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struct have shown that overexpression of the p65 subunit
of NF-nB, together with C/EBP factors, is able to activate
the reporter gene. This suggests that the two factors alone
are sufficient to sustain the activation of the IL-6 gene
[17,18].
The AP-1 transcription factors are homodimers and
heterodimers composed of basic region-leucine zipper pro-
teins that belong to the Jun and Fos subfamilies [19]. Fos
proteins do not form stable dimers, but can bind DNA by
forming heterodimers with Jun proteins. The DNA binding
affinities and transactivation capacities of the Jun proteins
vary considerably, with c-Jun exhibiting the highest activa-
tion potential [20]. AP-1 activity is induced by several
stimuli, such as serum, growth factors, oncoproteins, TNF-
a, and IL-1 [19,21].
Several lines of evidence suggest that members of the
NF-nB, C/EBP, and AP-1 transcription factor families may
work in concert to regulate the IL-6 promoter in a cell-type-
or inducer-specific fashion [17,18,22,23]. Indeed, a physical
and functional interplay among all three classes of proteins
has been widely demonstrated [7,24,25]. However, prior
studies have not clarified the contribution of each transcrip-
tion factor and its respective recognition site to IL-6
promoter activation.
In the present study, we have analyzed the role of various
cis-acting regulatory elements of the IL-6 promoter and of
the p65 subunit of NF-nB, c-Jun, and C/EBPy in the
transcriptional regulation of the IL-6 gene. We show that
an IL-6 promoter/reporter construct containing only the
TATA box and the NF-nB binding site was sufficient to
obtain the maximal activation of the reporter gene by
ectopically expressed p65, c-Jun, and C/EBPy. In addition,
we show by electrophoretic mobility shift assay (EMSA)
that p65 forms higher affinity and faster migrating com-
plexes with the nB site, in the presence of C/EBPy and/or c-
Jun or TAM-67. These results indicate that the complex
responsible for optimal transcription of the IL-6 gene
requires interaction between NF-nB, C/EBP, and c-Jun on
the nB site. Interestingly, TAM-67, a mutant form of c-Jun
lacking the transcriptional transactivation domain, activates
the IL-6 promoter with an efficiency much stronger than that
of c-Jun, suggesting that the c-Jun transactivation domain
may interfere with the formation of an optimal transcrip-
tional complex, in contrast to other transcriptional systems
studied to date [24–27].2. Materials and methods
2.1. Cell lines and treatments
HeLa cells were grown in DMEM supplemented with 20
mM glutamine, 50 Ag/ml gentamycin and 10% FBS (Bio-
Whittaker, Italy). TNF-a (specific activity 2 107 U/mg)
was obtained from Sigma.2.2. Plasmids
The plasmids pIL6(-592) and pIL6(-225) were obtained
by inserting the MscI/XhoI and NheI/XhoI fragments of the
human IL-6 gene promoter into pGL3 basic (Promega).
The pIL6( 100), pIL6( 80), and pIL6( 60) plasmids
were kindly provided by D.M. Klinman (Section of Retro-
viral Immunology Center for Biologics Evaluation and
Research, Food and Drug Administration, Bethesda,
USA). The pIL6( 592)/mut-nB was obtained by PCR
amplification using an oligonucleotide mutated in the nB
site which does not bind NF-nB (5V-AATGTAAT
ATTTTCCCATG-3V). The eukaryotic expression vectors
carrying the coding regions of p65 and InBa under control
of the CMV promoter were gifts of A. Israel (Institute
Pasteur, Paris, France) and P.A. Bauerle (University of
Freiburg, Germany), respectively. The expression vector
for C/EBPy which contains the C/EBPy coding sequence
downstream of the CMV promoter/enhancer sequence was
kindly provided by S. Akira and T. Kishimoto (Department
of Medicine III, Osaka University Medical School, Suita,
Japan). Expression vectors for c-Jun and TAM67 which
contain coding sequences for the proteins downstream to
the CMV promoter sequence were kindly provided by S.M.
Cole (Northwestern University Medical School, Chicago,
USA) and M.J. Birrer (National Cancer Institute, Rockville,
Maryland, USA), respectively. The pSVhgal plasmid was
obtained from Promega.
2.3. Transient transfection and reporter gene assay
Exponentially growing HeLa cells were seeded at a
density of 2.5 105 cells per well in six-well plates.
Twenty-four hours later, transfections were carried out with
Fugene6 Transfection Reagent (Roche) at a transfection
reagent/DNA ratio of 3:2. The total amounts of expression
vectors were kept constant by adding an empty pCMV
vector. In each transfection, 0.2 Ag of the plasmid pSVhgal
was added. Cells were incubated for 24 h, luciferase
activity was then determined using the Luciferase Assay
System (Promega) according to the manufacturer’s instruc-
tions and normalized with respect to the h-galactosidase
activity. Transfection efficiency was consistently about
15%.
2.4. In vitro translation and EMSA
In vitro transcription and translation of p65, C/EBPy, c-
Jun, and TAM-67 was carried out using the TNT coupled
Reticulocyte Lysate Systems (Promega). The translated
products obtained in the presence of 35S-methionine were
identified by molecular weight in SDS PAGE. The efficien-
cy of the translation was similar for all vectors. Binding
reactions were carried out in a final volume of 20 Al using 2
Al of in vitro translated product in 20 mM Tris pH 7.5, 100
mM KCl, 0.1 mM DTT, 1 mM EDTA, 0.1% NP-40, 5%
hysica Acta 1692 (2004) 17–24
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sham, Milan, Italy) and 1-Ag BSA. Radiolabelled probe
(0.02 pmol; sp. act. f 3 106 cpm/pmol) was added last to
each reaction mixture and samples were incubated at room
temperature for 30 min. In competition assays, a 200-fold
molar excess of cold double-stranded oligonucleotides was
added to the reaction mixture. Samples were then loaded on
a 5% (30:1.2) native polyacrylamide gel in 0.5 TBE and
run at 150 V, dried, and exposed to Kodak films.
The sequence of the IL6-nB oligonucleotide is as follows
(only the sequence of the ‘‘sense’’ strand is indicated): 5V-
AATGTGGGATTTTCCCATG-3V.3. Results
3.1. Induction of the IL-6 promoter by p65, C/EBPd or c-Jun
In order to clarify the concerted mechanism of NF-nB,
AP-1 and C/EBP interactions on the IL-6 promoter, we
focused our studies on p65, c-Jun, and C/EBPy, which
have been shown to be the most efficient activators of IL-
6 transcription with respect to other members of the
respective families [15,18,28, and our unpublished results].
The ability of p65, c-Jun, or C/EBPy to activate a 592-bp
IL-6 promoter luciferase reporter plasmid and various
deletion mutant constructs was assessed. The activation
of the  225 IL-6 promoter construct (Fig. 1) by p65 was
similar to that of the  592 construct, while further
deletions of the promoter up to  80 resulted in a
significant decrease of luciferase activity, similar to that
of the  60 construct. These results indicate that p65 is
unable to activate an IL-6 promoter construct containingFig. 1. Transient transfection of HeLa cells with deleted IL-6 promoter-reporter c
with 1 Ag of each promoter-luciferase reporter construct and 0.2 Ag of the vectors e
luciferase activity of the reporter plasmid in the presence of the expression vect
presented are the meansF S.D. of at least six independent experiments.only the TATA box and the nB site. C/EBPy activation
was optimal on the  225 construct, suggesting that the
region between  592 and  225 contains a negative
regulatory element. Successive deletions of the IL-6 pro-
moter up to nucleotides  100 and  80 resulted in a
progressive reduction in luciferase activity, indicating that
the upstream and the downstream C/EBP sites are both
relevant for the C/EBPy-mediated activity of the IL-6
promoter. Overexpression of c-Jun slightly activated the
 100 construct (Fig. 1), which does not contain the AP-1
site, suggesting that this site is not necessary for the
activation of the IL-6 promoter by c-Jun.
3.2. Synergistic activation of the IL-6 promoter by p65,
c-Jun, and C/EBPd
It has been widely demonstrated that p65, c-Jun, and C/
EBP physically interact with each other via the Rel
homology and the leucine zipper domains [7,24,25]. Then,
in order to examine the functional interactions between
p65, c-Jun, and C/EBPy within the IL-6 promoter, we
performed transfection experiments in HeLa cells with
combined ectopic expression of p65, c-Jun, and C/EBPy.
All deletion mutant constructs of the IL-6 promoter were
synergistically activated by association with p65/c-Jun,
p65/C/EBPy, and p65/c-Jun/C/EBPy, while only the
 100 and  80 constructs were synergistically activated
by c-Jun/C/EBPy (cf. Figs. 1 and 2). The contribution of c-
Jun to transcriptional activity was independent of the
presence of its own binding site ( 283/ 277), as dem-
onstrated in Fig. 1. C/EBPy showed the maximal trans-
activation potential on the  100 construct together with
p65 and on the  80 construct together with c-Jun. Thisonstructs: activation by p65, c-Jun or C/EBPy. HeLa cells were transfected
xpressing p65, c-Jun or C/EBPy. Values are represented as fold activation of
ors over the activity in the absence of the expression vectors. The results
Fig. 2. Transient transfection of HeLa cells with deleted IL-6 promoter-reporter constructs: synergic activation by p65, c-Jun and C/EBPy. HeLa cells were
transfected with 1 Ag of each promoter-luciferase reporter construct and 0.2 Ag of each of the vectors expressing p65, c-Jun and C/EBPy and 0.3 Ag of the
vector expressing InBa, as indicated. Values are represented as fold activation of luciferase activity of the reporter plasmid in the presence of the expression
vectors over the activity in the absence of the expression vectors. The results presented are the meansF S.D. of at least six independent experiments.
Fig. 3. Transient transfection of HeLa cells with a nB site mutated IL-6
promoter construct: lack of synergy between p65 and c-Jun or C/EBPy.
HeLa cells were transfected with 1 Ag of pIL6( 592) plasmid having a
point mutation in the nB site and 0.2 Ag of the vectors expressing p65, c-Jun
and C/EBPy, as indicated. Values are represented as fold activation of
luciferase activity of the reporter plasmid in the presence of the expression
vectors over the activity in the absence of the expression vectors. The results
presented are the meansF S.D. of at least six independent experiments.
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site, is important for the interaction of p65 with C/EBPy in
the absence of c-Jun. On the other hand, the  87/ 76 C/
EBP site is not required for the synergism of c-Jun with C/
EBPy, which depends exclusively on the nB site. Indeed,
overexpression of InBa together with c-Jun and C/EBPy
significantly reduced the activity of the  80 construct
(Fig. 2), suggesting that c-Jun and C/EBPy interact on the
nB site via the constitutively expressed NF-nB. In line
with this result, the maximal activation of each construct
was obtained with the association of p65, C/EBPy, and c-
Jun and reached the highest level on the  80 construct.
Taken together, these results demonstrate that both c-Jun
and C/EBPy are capable of activating the IL-6 promoter in
the absence of their respective binding sites, but require
the presence of the nB site and constitutive or overex-
pressed p65. According to this result, p65 alone did not
induce luciferase activity from a  592 construct contain-
ing a point mutation in the nB site nor did it synergize
with c-Jun or C/EBPy (Fig. 3). This indicates that p65 is
unable to functionally interact with c-Jun or C/EBPy on
their respective recognition sites.
3.3. Activation of the IL-6 promoter by a c-Jun lacking the
transactivation domain
To further characterize the mechanism of IL-6 tran-
scription activation by c-Jun, we performed transient
transfection assays with a vector expressing a dominantnegative mutant of c-Jun lacking the transactivation
domain (TAM-67) [25,26]. Surprisingly, cotransfection
of TAM-67 alone with the various deleted IL-6 promoter
constructs resulted in an activation of luciferase activity
stronger than that obtained with c-Jun and similar to that
observed with p65 overexpression (Fig. 4). Accordingly,
cotransfection of TAM-67 together with p65 and/or C/
EBPy gave rise to a much stronger activation than that
obtained with p65/c-Jun, c-Jun/C/EBPy, or p65/c-Jun/C/
Fig. 4. TAM-67 activates the IL-6 promoter and synergises with p65 and/or C/EBPy. HeLa cells were transfected with 1 Ag of each IL-6 promoter-luciferase
reporter construct and 0.2 Ag of each of the vectors expressing p65, C/EBPy, and 0.5 Ag of the vector expressing TAM-67, as indicated. Values are represented
as fold activation of luciferase activity of the reporter plasmid in the presence of the expression vectors over the activity in the absence of the expression
vectors. The results presented are the meansF S.D. of at least six independent experiments.
Fig. 5. TAM-67 is an activator of the IL-6 promoter stronger than c-Jun.
HeLa cells were transfected with 1 Ag of the pIL6( 100) promoter-
luciferase reporter construct, 0.2 Ag of the vector expressing p65 and
increasing amounts (0.1, 0.2, 0.5, 0.75, 1 Ag) of the vectors expressing c-Jun
and TAM-67, as indicated. Values are represented as fold activation of
luciferase activity of the reporter plasmid in the presence of the expression
vectors over the activity in the absence of the expression vectors. The results
presented are the meansF S.D. of at least five independent experiments.
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domain may interfere with the formation of the optimal
transcriptional complex on the IL-6 promoter. A control
experiment demonstrated that TAM-67 was able to act in
a dominant negative fashion by inhibiting c-Jun activity
on TRE-CAT, an AP-1 responsive reporter plasmid (data
not shown). Fig. 5 shows that TAM-67 activated the
 100 IL-6 promoter construct in synergy with p65 in a
dose-dependent manner, while c-Jun did not provide
greater activity at higher concentrations. Thus, TAM-67
specifically transactivates the IL-6 promoter, while it
behaves as a dominant negative factor on an AP-1
responsive construct.
3.4. EMSA with in vitro translated p65, C/EBPd, c-Jun and
TAM-67
To assay directly whether C/EBPy, c-Jun, and/or TAM-
67 were physically associated with p65, EMSAs were
performed using a 32P-labelled oligonucleotide corres-
ponding to the NF-nB binding site on the 5V-regulatory
region of the human IL-6 gene and in vitro translated p65,
C/EBPy, c-Jun, and TAM-67. As shown in Fig. 6, a
specific protein–DNA complex was observed with the
p65 protein, as demonstrated by competition with an excess
of the unlabelled oligonucleotide (lanes 1 and 2). C/EBPy,
c-Jun, and TAM-67 did not form any specific complex
when incubated with the probe (lanes 3, 5 and 7). However,
in the presence of p65, each factor determined the appear-
Fig. 6. EMSA with in vitro translated p65, C/EBPy, c-Jun and TAM-67. A 32P labelled oligonucleotide corresponding to the NF-nB binding site on the 5V-
regulatory region of the human IL-6 gene was incubated with 2 Al of in vitro translated p65, c-Jun, TAM-67 and C/EBPy, as indicated. Lane 2: specific
competition with 200-fold excess of the unlabelled oligonucleotide. Lane 11: EMSA control with the in vitro translation product from an empty CMV vector.
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stronger intensity (lanes 4, 6 and 8) compared to the
complex obtained with p65 alone (lane 1). Incubation of
p65 with C/EBPy and c-Jun or TAM-67 further increased
the mobility and the intensity of the complex (lanes 9 and
10). These results strongly suggest that C/EBPy and/or c-
Jun or TAM-67 interact with p65 forming complexes with
altered subunits composition and structural conformation,
which would be responsible for differential migration and
affinity of the complex. It has already been demonstrated,
indeed, that p65 binds to its specific site as a homodimer,
while its interaction with C/EBPy or c-Jun is likely to be
heterodimeric [24]. Moreover, it is known that both NF-nB
and Jun/Fos induce DNA bending, which increases the
electrophoretic complex mobility [24]. Remarkably, TAM-
67 determined the formation of a complex with p65 and/or
C/EBPy having higher intensity compared to c-Jun. This
observation supports our transfection data showing a stron-
ger functional synergism of TAM-67 with p65 and C/EBPy
compared to c-Jun.4. Discussion
This study provides evidence for a strong synergism
among members of the NF-nB, C/EBP, and AP-1 families
of transcription factors, which occurs on the interleukin-6
promoter and requires only the NF-nB binding site. In
addition, our data demonstrate that a mutated form of c-
Jun lacking 120 amino acids of the N-terminal trans-
activation domain, namely TAM-67, is a strong activator
of the IL-6 promoter. Indeed, transient transfection of
HeLa cells showed that either alone or in association
with p65 and/or C/EBPy, TAM-67 was capable of acti-
vating all the IL-6 promoter-reporter constructs tested,
even in the absence of its own binding site, provided
that the nB element was present. The overexpression of c-
Jun also determined a similar but weaker pattern of IL-6promoter activation, suggesting that the c-Jun transactiva-
tion domain may interfere with the formation of an
optimal transcriptional complex, as opposed to other
transcriptional systems [24–27]. Consistent with our data,
the TNF-a promoter was also activated by TAM-67 [29].
However, in contrast to our results, TAM-67 required the
presence of an AP-1 binding site in order to activate the
TNF-a promoter. The observation that c-Jun is a superior
activator of the IL-6 and the TNF-a promoters when the
transactivation domain is not present suggests a novel role
for this transcription factor. Indeed, one may speculate
that on these promoters c-Jun may behave as an adapter
protein that stabilizes the multimeric transcription com-
plex, increasing its activity. In other transcriptional sys-
tems [24–27], c-Jun would behave as an active member
of the complex and synergism with other transcription
factors would result from the combined usage of all
transactivation domains.
AP-1 represents a key family of transcription factors
transducing multiple mitogenic signals. Thus, dominant
negative mutants of these proteins, such as TAM-67, have
been designed as possible inhibitors of cancer cell growth
[25,30]. It has been recently demonstrated that TAM-67
inhibits the proliferation of some breast cancer cell lines
(MCF-7), while it is ineffective on others (MDA-MB-231)
[31]. Our data on the activation of the IL-6 promoter by
TAM-67 together with observations on the TNF-a promoter
[29] suggest that the differential growth inhibitory effect
obtained in various cell lines may be ascribed to the ability
of TAM-67 to differentially regulate target genes such as IL-
6, TNF-a, or other not yet identified TAM-67 inducible
genes which may be responsible for cellular growth.
The IL-6 promoter comprises several control regions
that can be triggered by multiple pathways [1]. Physiolog-
ical inducers of IL-6 gene expression, such as IL-1 [18]
and TNF-a [18,28], require the presence of an intact nB
site for IL-6 promoter activation. Furthermore, it has been
suggested that NF-nB alone is both responsible and
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TNF-a are powerful activators not only of NF-nB [7], but
also of C/EBP [7,15,16] and AP-1 [19]. Our data demon-
strate that the p65 subunit of NF-nB cotransfected with the
 80 IL-6 promoter-reporter gene construct containing
only the TATA box and the nB site is unable to induce
luciferase activity by itself, while it strongly synergizes
with C/EBPy and/or c-Jun or TAM-67. Hence, these
results suggest that NF-nB alone is not sufficient for the
responsiveness of the IL-6 promoter to IL-1 or TNF-a.
Indeed, the contemporary activation of AP-1 and/or C/EBP
by IL-1 or TNF-a may be necessary for the formation of
an active transcription complex requiring interaction on the
nB site between NF-nB and AP-1 and/or C/EBP. Transient
transfection assays performed with the nB point mutated
IL-6 promoter construct demonstrate that p65 is unable to
functionally interact with either c-Jun or C/EBPy on their
respective recognition sites as described for other systems
[24,32]. This finding suggests that the functional syner-
gism between p65 and c-Jun or C/EBPy may occur only
on the nB site (located at positions  75/ 63) of the IL-6
promoter, most likely due to its proximity to the TATA
box, which would allow optimal association with the basal
transcription complex. Moreover, our EMSA data showing
the formation of higher affinity and migrating complexes
between p65, C/EBPy and/or c-Jun or TAM-67 on the nB
site strongly support the idea that the functional synergism
is determined by a physical interaction.
In conclusion, our results provide evidence that the most
favorable complex responsible for the transcription of the
IL-6 gene requires the interaction between p65 and C/EBPy,
and c-Jun occurring on the nB site. Moreover, c-Jun is
capable of interacting with the complex in a manner that
does not require the transactivation domain, suggesting it
has a role as an adapter protein in the context of the IL-6
promoter activation.Acknowledgements
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